PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
AbbVie Inc (4AB.DE)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS00287Y1091
SectorHealthcare
IndustryDrug Manufacturers - General

Highlights

Market Cap€316.39B
EPS (TTM)€2.74
PE Ratio65.29
PEG Ratio0.47
Total Revenue (TTM)€41.07B
Gross Profit (TTM)€27.07B
EBITDA (TTM)€14.78B
Year Range€121.75 - €181.20

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons: 4AB.DE vs. NOV.DE, 4AB.DE vs. SPY

Performance

Performance Chart

The chart shows the growth of an initial investment of €10,000 in AbbVie Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-5.00%0.00%5.00%10.00%15.00%20.00%MayJuneJulyAugustSeptemberOctober
17.50%
12.93%
4AB.DE (AbbVie Inc)
Benchmark (^GSPC)

Returns By Period

AbbVie Inc had a return of 31.63% year-to-date (YTD) and 31.06% in the last 12 months. Over the past 10 years, AbbVie Inc had an annualized return of 20.63%, outperforming the S&P 500 benchmark which had an annualized return of 12.04%.


PeriodReturnBenchmark
Year-To-Date31.63%22.85%
1 month2.22%4.16%
6 months17.87%15.77%
1 year31.06%35.40%
5 years (annualized)26.86%14.46%
10 years (annualized)20.63%12.04%

Monthly Returns

The table below presents the monthly returns of 4AB.DE, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20249.49%7.51%2.82%-8.96%-3.91%9.07%10.23%1.82%-0.33%31.63%
2023-11.02%7.79%0.72%-5.40%-5.43%-4.19%10.33%1.49%4.25%-5.97%-1.89%7.85%-3.82%
20223.23%7.61%12.71%-7.15%1.06%6.25%-5.24%-2.02%3.59%6.95%3.71%-0.37%32.69%
20210.70%3.72%3.94%2.61%0.99%1.60%5.17%3.78%-7.79%6.17%3.66%16.46%47.46%
2020-5.25%3.56%-6.88%8.53%8.24%4.91%-5.19%0.76%-6.21%-4.08%22.06%-1.62%16.23%
2019-9.68%-0.67%2.84%-0.33%-2.61%-7.24%-4.52%-0.00%17.00%2.90%12.08%-2.01%4.89%
201811.61%7.77%-21.26%7.72%5.31%-6.28%-1.75%6.17%-1.93%-14.46%16.06%-1.60%0.64%
2017-5.29%4.12%4.38%0.15%-3.02%7.82%-5.51%4.35%21.58%3.70%4.50%0.77%41.09%
2016-1.70%-1.57%-2.74%7.25%6.70%-2.40%7.57%-2.95%-2.17%-6.83%12.25%3.66%16.39%
20150.50%-0.15%-0.66%8.31%4.47%-0.93%5.55%-11.75%-14.97%10.85%5.24%-3.98%-0.85%
2014-3.46%0.47%0.69%0.14%6.43%3.96%-3.26%5.39%10.45%8.63%9.84%-2.46%41.80%
20131.20%3.18%13.37%11.42%-2.83%-5.78%6.82%-5.13%0.34%9.88%-0.27%6.85%43.76%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current risk-adjusted rank of 4AB.DE is 81, placing it in the top 19% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of 4AB.DE is 8181
Combined Rank
The Sharpe Ratio Rank of 4AB.DE is 8484Sharpe Ratio Rank
The Sortino Ratio Rank of 4AB.DE is 7777Sortino Ratio Rank
The Omega Ratio Rank of 4AB.DE is 7777Omega Ratio Rank
The Calmar Ratio Rank of 4AB.DE is 8989Calmar Ratio Rank
The Martin Ratio Rank of 4AB.DE is 7878Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for AbbVie Inc (4AB.DE) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


4AB.DE
Sharpe ratio
The chart of Sharpe ratio for 4AB.DE, currently valued at 1.58, compared to the broader market-4.00-2.000.002.004.001.58
Sortino ratio
The chart of Sortino ratio for 4AB.DE, currently valued at 2.12, compared to the broader market-4.00-2.000.002.004.002.12
Omega ratio
The chart of Omega ratio for 4AB.DE, currently valued at 1.28, compared to the broader market0.501.001.502.001.28
Calmar ratio
The chart of Calmar ratio for 4AB.DE, currently valued at 1.88, compared to the broader market0.002.004.006.001.88
Martin ratio
The chart of Martin ratio for 4AB.DE, currently valued at 5.85, compared to the broader market-10.000.0010.0020.0030.005.85
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.78, compared to the broader market-4.00-2.000.002.004.002.78
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.70, compared to the broader market-4.00-2.000.002.004.003.70
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.50, compared to the broader market0.501.001.502.001.50
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 2.45, compared to the broader market0.002.004.006.002.45
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 16.98, compared to the broader market-10.000.0010.0020.0030.0016.98

Sharpe Ratio

The current AbbVie Inc Sharpe ratio is 1.58. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of AbbVie Inc with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.501.001.502.002.503.00MayJuneJulyAugustSeptemberOctober
1.58
2.43
4AB.DE (AbbVie Inc)
Benchmark (^GSPC)

Dividends

Dividend History

AbbVie Inc granted a 2.40% dividend yield in the last twelve months. The annual payout for that period amounted to €4.29 per share.


PeriodTTM20232022202120202019201820172016
Dividend€4.29€5.43€5.38€4.37€4.17€3.37€2.79€2.23€1.96

Dividend yield

2.40%3.87%3.53%3.67%4.88%4.31%3.54%2.73%3.26%

Monthly Dividends

The table displays the monthly dividend distributions for AbbVie Inc. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024€1.42€0.00€0.00€1.46€0.00€0.00€1.42€0.00€0.00€0.00€4.29
2023€1.36€0.00€0.00€1.34€0.00€0.00€1.32€0.00€0.00€1.41€0.00€0.00€5.43
2022€1.23€0.00€0.00€1.30€0.00€0.00€1.41€0.00€0.00€1.44€0.00€0.00€5.38
2021€1.07€0.00€0.00€1.09€0.00€0.00€1.10€0.00€0.00€1.12€0.00€0.00€4.37
2020€1.06€0.00€0.00€1.07€0.00€0.00€1.04€0.00€0.00€1.00€0.00€0.00€4.17
2019€0.81€0.00€0.00€0.84€0.00€0.00€0.84€0.00€0.00€0.88€0.00€0.00€3.37
2018€0.59€0.00€0.00€0.78€0.00€0.00€0.70€0.00€0.00€0.72€0.00€0.00€2.79
2017€0.60€0.00€0.00€0.60€0.00€0.00€0.56€0.00€0.00€0.46€0.00€0.00€2.23
2016€0.48€0.00€0.00€0.45€0.00€0.00€0.51€0.00€0.00€0.52€0.00€0.00€1.96

Dividend Yield & Payout


Dividend Yield
5.0%10.0%15.0%2.4%
AbbVie Inc has a dividend yield of 2.40%, which is quite average when compared to the overall market.
Payout Ratio
200.0%400.0%600.0%800.0%1.7%
AbbVie Inc has a payout ratio of 1.67%, which is below the market average. This means AbbVie Inc returns a smaller proportion of its earnings to shareholders as dividends, suggesting it retains a higher portion for reinvestment, growth, or debt payment.

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-14.00%-12.00%-10.00%-8.00%-6.00%-4.00%-2.00%0.00%MayJuneJulyAugustSeptemberOctober
-0.62%
0
4AB.DE (AbbVie Inc)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the AbbVie Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the AbbVie Inc was 36.94%, occurring on Aug 14, 2019. Recovery took 124 trading sessions.

The current AbbVie Inc drawdown is 0.62%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-36.94%Jan 30, 2018380Aug 14, 2019124Feb 12, 2020504
-32.89%Feb 14, 202027Mar 23, 202081Jul 20, 2020108
-29.21%Jul 21, 2015141Feb 11, 2016268Mar 10, 2017409
-22.07%Jan 9, 2023120Jun 28, 2023144Jan 19, 2024264
-21.92%Jul 21, 202072Oct 28, 202019Nov 24, 202091

Volatility

Volatility Chart

The current AbbVie Inc volatility is 3.95%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%3.00%4.00%5.00%6.00%7.00%8.00%MayJuneJulyAugustSeptemberOctober
3.95%
2.93%
4AB.DE (AbbVie Inc)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of AbbVie Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Valuation

The Valuation section provides an assessment of the market value of AbbVie Inc compared to its peers in the Drug Manufacturers - General industry.


PE Ratio
20.040.060.080.0100.0120.065.3
The chart displays the price to earnings (P/E) ratio for 4AB.DE in comparison to other companies of the Drug Manufacturers - General industry. Currently, 4AB.DE has a PE value of 65.3. This PE ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.
PEG Ratio
10.020.030.00.5
The chart displays the price to earnings to growth (PEG) ratio for 4AB.DE in comparison to other companies of the Drug Manufacturers - General industry. Currently, 4AB.DE has a PEG value of 0.5. This PEG ratio falls in the average range for the industry.

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for AbbVie Inc.


Loading data...

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items